Purpose: The purpose of this study was to determine the time required for antimicrobial stewardship (AS) activities at a small community hospital (SCH) as well as barriers to remote AS to satisfy The Joint Commission (TJC)'s AS standard. Methods: This was a prospective chart review and time study conducted in patients identified by a clinical decision support application as potential opportunities for antimicrobial therapy modification at a SCH between December 12, 2016, and March 31, 2017. Potential interventions were communicated electronically to the clinical pharmacy specialist, who would then communicate the recommendations to the patient's provider. The primary endpoint was a time study for stewardship activities. Secondary endpoints included describing barriers encountered to remote AS as well as a cost-benefit analysis of remote AS. Results: The time study revealed an average of 11 alerts per day, 9 chart reviews per day, 8 interventions per day, and 5 minutes per chart. Seven hundred twenty-four alerts were evaluated with the most common alerts constituting opportunities for deescalation (29%), targeted drugs (22%), positive blood cultures (18%), Intravenous (IV) to oral (PO) (17%), and antimicrobial renal monitoring (8%).Interventions were accepted (11%), accepted modified (6%), rejected (35%), or undetermined (48%). Barriers to implementation included workflow and indirect communication. For patients with accepted interventions, there was an average savings of $279.82 per patient in pharmacy charges. Conclusion: Through remote AS, a SCH can have an antimicrobial stewardship program that is in compliance with the basic elements of the TJC standard MM.09.01.01, performs daily chart review by an infectious diseases trained pharmacist to increase the quality of patient care, and achieves a mean savings of $279.82 in pharmacy charges and $1,126.26 in hospital charges per patient with accepted interventions.
Introduction
With increasing rates of resistance, hospital-acquired infections, and a shift from pay for service to value-based services, there has been increasing awareness that the use of antimicrobial agents needs to be evaluated and optimized. [1] [2] [3] [4] [5] [6] [7] [8] [9] In 2007, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recognized that antimicrobial stewardship (AS) could be a self-supporting tool to address these growing concerns. This led to the publication of guidelines for developing antimicrobial stewardship programs (ASP). 10 Since then, there have been numerous attempts to determine the optimal structure of an ASP with various results. [1] [2] [3] 5, [8] [9] [10] [11] [12] [13] [14] Multiple national organizations have also recognized the need for ASP and have developed a tool or guidelines for ASP including the White House, The National Quality Forum, the Centers for Disease Control and Prevention, IDSA, and SHEA. 2, 4, 8, 9 The Joint Commission (TJC) has also recognized the importance of AS by requiring ASP through standard MM.09.01.01 effective January 1, 2017. The standard notes that "part-time or consultant staff are acceptable as members of the antimicrobial stewardship multidisciplinary team" and "telehealth staff are acceptable as members of the antimicrobial stewardship multidisciplinary team." 7 IDSA has also released a position statement in favor of using telehealth for ASP. 15 A recent study by Echevarria and colleagues derived a calculator to guide staffing requirements for ASPs within the Veterans Affairs (VA) system. They determined that 1 pharmacist full-time equivalent (FTE) was needed per 100 patient beds. However, the main hospitals evaluated were teaching hospitals with half of the evaluated hospitals serving patient populations with increased comorbidities.
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Small community hospitals (SCH) cannot often financially support hiring an infectious diseases (ID) trained physician or pharmacist solely to implement and conduct an ASP. There have been attempts in the literature to find a way for SCH to create an ASP but they often involve hiring an ID physician champion or repurposing resources from a large hospital within a health system. 1, 3, 6, 16 To date, there is no data describing how much time is required to conduct stewardship a SCH, the ability of a pharmacy-driven stewardship program to be conducted remotely, and the use of Theradoc as a specific clinical decision support (CDS) tool for stewardship. We sought to describe the feasibility of having a postgraduate year 2 ID pharmacy resident, herein referred to as the remote pharmacist, conduct remote AS for one of Emory Healthcare's smaller hospitals, Emory John's Creek Hospital (EJCH), a 110-bed suburban hospital. The resident would be responsible for ensuring compliance with the new TJC stewardship standard requirements as well as prompted chart review. The purpose of this study was to determine the time required for AS activities at a SCH as well as barriers to remote AS in order to satisfy TJC's AS standard.
Methods

Study Design
This was an institutional review board-approved prospective chart review conducted from December 12, 2016, to March 31, 2017, at EJCH. All Emory Healthcare hospitals utilize the same electronic medical record (EMR) as well as the same CDS and electronic surveillance tool, Theradoc. The primary outcome of this study was to describe and characterize the time commitment required for AS at a SCH. Secondary outcomes included the identification of barriers to AS and a cost-benefit analysis at a SCH. Patients were included if they were admitted to EJCH and met Theradoc alert criteria. Patients were excluded if they were less than 18 years of age because this patient population is not common at the SCH and there was concern for skewing the data, the qualifying antibiotic was for surgical prophylaxis as there was not enough time to intervene on the antimicrobial prior to use and discontinuation, or if the patient was discharged or deceased upon initial review due to the lack of ability to intervene while the patient was inpatient. Because this study is a descriptive study, all statistics were descriptive including differences, averages, and percentages.
Regulatory Compliance
The remote pharmacist worked with a multidisciplinary team to ensure the ASP's compliance with the new TJC standard. There are 8 components to the TJC standard MM.09.01.01 including (1) organizational priority, (2) education of hospital employees, (3) education of patients and families, (4) multidisciplinary team, (5) core elements, (6) organization-approved multidisciplinary protocols, (7) collects, analyzes, and reports data, and (8) the hospital takes action on improvement opportunities.
Chart Review
The remote pharmacist would review the Theradoc alerts daily. The alerts were predetermined to be those currently in use at one of the other hospitals using Theradoc for AS (Table 1) . When an alert fired, this would trigger a chart review by the remote pharmacist for possible AS interventions (Table 2) . If, upon chart review, the remote pharmacist thought an intervention was warranted, she would create an intervention in Theradoc and assign it to the sole clinical pharmacy specialist at the SCH. On a daily basis, the clinical pharmacy specialist at the SCH would review Theradoc for interventions from the remote pharmacist. He would then review the recommended interventions and communicate them to the patient providers as appropriate. In addition, the clinical pharmacy specialist is responsible for rounding in the intensive care unit (ICU), pharmacokinetics for the entire hospital, total parenteral nutrition for the entire hospital, anticoagulation for his unit, and is responsible for reviewing and addressing Theradoc alerts. Theradoc interventions were communicated to the clinical pharmacy specialist in order to capitalize on preestablished relationships with providers, knowledge of nuances of the hospital's preferences and standards, and the ability to speak with providers in person. Intervention acceptance status was documented via Theradoc.
At the end of each month, a review of barriers, number of alerts, and number of interventions were assessed. At the end of February, it was decided that the remote pharmacist would no longer evaluate alerts that could be addressed through pharmacy protocols or for patients in the ICU where the clinical pharmacy specialist participated in multidisciplinary rounds. At Emory, pharmacists can only make medication changes without direct permission from the provider if there is a protocol in place that has been approved by the Note: IV = intravenous; PO = oral; MRSA = methicillin-resistant Staphylococcus aureus; MIC = minimum inhibitory concentration; MSSA = methicillin-susceptible Staphylococcus aureus; TDM = therapeutic drug monitoring; CrCI = creatinine clearance appropriate provider committees. Otherwise, all proposed changes had to have the explicit permission of the provider. Existing protocols relating to antimicrobial therapy included evaluating the need for vancomycin for greater than 72 hours (changes still required provider permission), IV to PO conversions, and antimicrobial renal monitoring.
Cost-Benefit Analysis
The cost-benefit analysis was determined by total hospital charges. For patients with an accepted intervention, the pharmacy charges were evaluated for savings or increased expense.
Results
Regulatory Compliance
(1) To meet the criteria for organizational priority, a formal AS policy and strategic plan were created and accepted by the necessary regulatory bodies. (2) To meet the education of hospital employees, a PowerPoint presentation was distributed to pharmacists as well as mentioned in the monthly pharmacy meetings. The results of this study and the importance of AS were also emphasized when presented to hospitalists at the SCH. (3) Education of patients and families was accomplished through the administration of discharge handouts if the patient was discharged on an antimicrobial, as well as one of the Centers for Disease Control and Prevention Get Smart Handouts. (4) The study team for this project was a multidisciplinary team consisting of pharmacists and physicians. The AS members were also members of the Antimicrobial Utilization Committee (AUC) which consists of pharmacists, physicians, microbiologists, and more. (5) TJC's core elements for AS were met through the chart review portion of the study as well as contributions to AUC. (6) The ASP policy, pharmacist-driven protocols such as antimicrobial renal adjustments, and disease state-specific order sets were designed and approved by AUC and other regulatory bodies as appropriate. (7) Retrospective data were collected in the form of medication utilization evaluations as well as tracking of utilization rates. This information was analyzed and reported to AUC as well as targeted information to provider groups. (8) The strategic plan allowed for a targeted approach to capitalize on improvement opportunities. During the almost 3½-month-long study, a total of 3039 minutes were spent on ensuring regulatory compliance other than direct patient care. This averages out to 218 minutes per week or 3.6 hours per week. That time was distributed as 41.1% data analysis, 20.5% reporting, 18.4% preparing for AUC meetings, 14.6% education, and 5.4% regulatory protocols and policies.
Chart Review
There were 770 alerts (587 patient charts) for possible antimicrobial therapy modification over the study period. Twentythree alerts were excluded due to discharged status, 19 alerts were excluded as the alert applied to surgical prophylaxis antimicrobials, and 3 alerts were excluded due to age. Seven hundred twenty-four alerts were reviewed equating to 553 patients and 716 interventions. The average age was 63.5 ± 18.8 years with 50.8% being female. The average length of stay was 10 ± 10 days with an in hospital mortality rate of 8%.
On average, there were 11 ± 6 alerts (9 ± 4 patient charts) for the remote pharmacist to review per day. That took 45 minutes total with an average of 5 minutes per chart. The remote pharmacist recommended an average of 1 recommendation per chart.
Over the study period, the most common alerts were deescalation opportunities (29%), targeted drugs (22%), positive blood cultures (18%), IV to PO opportunities (17%), and antibiotic renal monitoring (8%). The most common interventions, indications for antimicrobials, and prescribed antimicrobials can be found in Tables 3, 4 , and 5 respectively. More than half (260/443, 59%) of the patient charts reviewed did not have growth on collected cultures.
Over the study period, 48% of interventions were undetermined, 35% rejected, 11% accepted, and 6% accepted modified. The undetermined interventions were patients who were discharged after chart review but before the clinical pharmacy specialist could intervene (43%), the intervention was implemented by the primary team prior to pharmacy intervention (16%), and other with unclear reasons (41%). With the targeted interventions in March, the acceptance rates increased from an overall of 11% accepted to 16%, and accepted modified from an overall of 6% to 7%. Common reasons for rejection included deferred to ID (28%), provider wanted to continue (20%), incomplete chart review/ missing information (8%), practice variation (8%), and clinical change (2%).
Barriers identified during the chart review included workflow, lack of communication, and lack of consistency. For workflow, the remote pharmacist would typically perform the chart review at the end of the day to allow for new culture results from the microbiology lab. This meant that the remote pharmacist's interventions were likely not reviewed until the next morning or afternoon. If the interventions were made on a Friday, they may not have been reviewed until the following Monday. This disparity in time to review the potential interventions likely contributed to the large percentage of interventions that were not implemented. The clinical pharmacy specialist also incorporated these additional interventions into an already busy workflow. Due to the electronic means of communication, one of the other largest barriers to remote AS was the lack of ability to have a dialogue about the possible intervention, address any possible concerns, and provide education when applicable by the remote pharmacist. Because the AS tasks were divided between chart review and screening for the remote pharmacist and implementation for the clinical pharmacy specialist, there was also a lack of consistency in message, delivery, and ability to ascertain practice variations during the 3½ months.
Cost-Benefit Analysis
Hospital charges for all patients evaluated were an average of $71,448.49. Patients with rejected interventions had an average hospital charge of $87,733.25 compared with $70,322.23 for patients with accepted interventions. The difference between total hospital charges for all patients and those with accepted interventions was $1,126.26. The difference between total hospital charges for patients with rejected interventions compared with patients with accepted interventions was $17,411.02. For patients with accepted interventions (excluding those that were accepted modified), an estimated total of $10,073 was saved in pharmacy charges alone over the 3½-month time frame. On average, this saved individual patients $279.82 in pharmacy charges.
Discussion
The most common indications for antimicrobials were largely pneumonia and urinary tract infections in this study. This both correlates with the literature and corroborates with the acuity of a typical SCH. 17 Given the most common indications, it is no surprise that the most common antimicrobials involved in the CDS-prompted chart reviews were vancomycin, piperacillin-tazobactam, ceftriaxone, and levofloxacin. Interestingly, however, more than half of the patients did not have any microbiologic data. A lack of microbiologic data compounds the complexity of ASP chart review by not having hard data to support most de-escalation principles where appropriate. This may have contributed to the relatively low acceptance rates of this study but could have also been influenced by the significant amount of pneumonia prompting antimicrobials. Most of the patients who were diagnosed with pneumonia did not have cultures collected. Of those who did, many did not have growth of an organism. This could have been due to the 2007 community-acquired pneumonia guidelines that indicate sputum cultures are optional in most patients secondary to a low sensitivity. 18 While the patient chart review has led to internal discussions for more pharmacy-driven protocols, increased utilization of existing protocols (eg, IV to PO conversions), as well as increased awareness of the importance of reliable microbiologic data, this study also illuminates reasonable expectations of an AS pharmacist. To the best of the authors' knowledge, this is the first time study of remote AS activities in a SCH. In this study, we found that an ID-trained pharmacist using Theradoc as a CDS tool can spend an average of 45 minutes per day on patient chart review for a 110-bed suburban hospital to identify and recommend needed therapy modifications. However, this does not include the time necessary Note. ID = infectious diseases. 17, [19] [20] [21] [22] In a study by Tamma and colleagues, the use of preprescription authorization or postprescription review with feedback were evaluated as AS strategies. This study ultimately found that postprescription review with feedback had more of an impact on decreasing days of therapy than preprescription authorization. 17 This lends itself to the idea of using a CDS tool as a means for remote AS through postprescription review with feedback. However, Pollara and colleagues found a higher intervention rate when a pharmacist was physically present for medical and surgical rounds instead of performing AS over the phone. 22 When an ASP pharmacist has been on site for intervention implementation, the literature has demonstrated an acceptance rate of around 90%. 23 The acceptance rate for this study was significantly lower at 11% overall and 16% with targeted interventions in the month of March. Possible barriers identified for remote AS included workflow, lack of communication, and lack of consistency. Workflow and timeliness have been barriers previously identified for ASP in the literature. 19 However, the authors propose that a lack of communication and lack of consistency are unique to realm of remote AS and may have significantly contributed to the lower acceptance rates of this study. We believe this highlights the importance of incorporating ID trained personnel, including pharmacists, into the implementation phase of AS which has been echoed in a recent systematic review of ASPs in the emergency department (ED) as well as a study that indicated 1 pharmacist FTE may be required per 100 patient beds at hospitals of high acuity. 11, 19 If the identified barriers can be overcome, there is also the potential to share an ID trained pharmacist to conduct AS among several SCH depending on bed size and acuity to decrease cost to the facility. The cost-benefit analysis demonstrated that an average of 7½ hours per week spent on chart review and regulatory compliance saved an estimated $10,073 in pharmacy charges over 3½ months. This time study could potentially be used to determine what is feasible for one pharmacist to cover for multiple hospitals while ensuring compliance with standard MM.09.01.01.
Future directions for possible remote ASP to overcome the identified barriers include more selective antimicrobial alerts, an on-call ASP pharmacist, ASP rounds, more pharmacy-driven protocols, and a dedicated ASP pharmacist.
Conclusion
Through remote AS, a SCH can have an ASP program that is in compliance with the basic elements of the TJC standard MM.09.01.01, performs daily chart review by an ID trained pharmacist to increase the quality of patient care, and has a mean savings of $279.82 in pharmacy charges and $1,126.26 in hospital charges per patient with accepted interventions.
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